STOCK TITAN
  1. Home
  2. Sec-filings
  3. GLPG
  4. [6-K] Galapagos NV Current Report (Foreign Issuer)

[6-K] Galapagos NV Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Galapagos NV (ticker: GLPG) filed a Form 6-K on 20 June 2025. The submission is primarily administrative in nature. It:

  • Announces that a press release dated 18 June 2025 is furnished as Exhibit 99.1.
  • States that the information in the report—excluding specific physician quotations in the exhibit—is incorporated by reference into multiple outstanding Form S-8 registration statements.
  • Contains no financial statements, earnings metrics, or details on material transactions.
  • Is signed by Company Secretary Annelies Denecker.
The filing therefore serves to place the 18 June 2025 press release into the SEC record but does not itself provide new operational or financial information that would affect the current investment thesis.

Galapagos NV (simbolo: GLPG) ha presentato un modulo 6-K il 20 giugno 2025. La comunicazione ha principalmente carattere amministrativo. Essa:

  • Annuncia che un comunicato stampa datato 18 giugno 2025 è allegato come Exhibit 99.1.
  • Dichiara che le informazioni contenute nel rapporto—ad eccezione delle citazioni specifiche di medici presenti nell'allegato—sono incorporate per riferimento in diversi moduli di registrazione Form S-8 ancora validi.
  • Non include bilanci, indicatori di redditività o dettagli su operazioni rilevanti.
  • È firmata dalla Segretaria Aziendale Annelies Denecker.
La presentazione ha quindi lo scopo di inserire il comunicato stampa del 18 giugno 2025 nel registro della SEC, ma non fornisce nuove informazioni operative o finanziarie che possano influenzare l'attuale tesi di investimento.

Galapagos NV (símbolo: GLPG) presentó un Formulario 6-K el 20 de junio de 2025. La presentación es principalmente de carácter administrativo. Este:

  • Anuncia que un comunicado de prensa fechado el 18 de junio de 2025 se adjunta como Exhibit 99.1.
  • Indica que la información en el informe—excepto las citas específicas de médicos en el anexo—se incorpora por referencia en varios formularios de registro Form S-8 vigentes.
  • No contiene estados financieros, métricas de ganancias ni detalles sobre transacciones materiales.
  • Está firmado por la Secretaria de la Compañía, Annelies Denecker.
Por lo tanto, la presentación sirve para incluir el comunicado de prensa del 18 de junio de 2025 en el registro de la SEC, pero no aporta nueva información operativa o financiera que pueda afectar la tesis de inversión actual.

Galapagos NV(티커: GLPG)는 2025년 6월 20일에 Form 6-K를 제출했습니다. 이 제출은 주로 행정적인 성격을 띠고 있습니다. 내용은 다음과 같습니다:

  • 2025년 6월 18일자 보도자료가 Exhibit 99.1로 제공되었음을 알립니다.
  • 보고서 내 정보는—첨부된 특정 의사 인용문을 제외하고—여러 유효한 Form S-8 등록 서류에 참조로 포함되어 있음을 명시합니다.
  • 재무제표, 수익 지표 또는 주요 거래 내역은 포함되어 있지 않습니다.
  • 회사 비서인 Annelies Denecker가 서명하였습니다.
따라서 이 제출은 2025년 6월 18일 보도자료를 SEC 기록에 포함시키기 위한 것이며, 현재 투자 논리에 영향을 줄 새로운 운영 또는 재무 정보를 제공하지 않습니다.

Galapagos NV (symbole : GLPG) a déposé un formulaire 6-K le 20 juin 2025. Cette soumission est principalement de nature administrative. Elle :

  • Annonce qu’un communiqué de presse daté du 18 juin 2025 est fourni en tant qu’Exhibit 99.1.
  • Indique que les informations contenues dans le rapport—à l’exception des citations spécifiques de médecins dans l’exhibit—sont incorporées par référence dans plusieurs déclarations d’enregistrement Form S-8 en cours.
  • Ne contient pas d’états financiers, de mesures de résultats ou de détails sur des transactions importantes.
  • Est signée par la secrétaire de la société, Annelies Denecker.
Le dépôt sert donc à inclure le communiqué de presse du 18 juin 2025 dans le dossier de la SEC, mais ne fournit pas de nouvelles informations opérationnelles ou financières susceptibles d’affecter la thèse d’investissement actuelle.

Galapagos NV (Ticker: GLPG) reichte am 20. Juni 2025 ein Formular 6-K ein. Die Einreichung ist hauptsächlich administrativer Natur. Sie:

  • kündigt an, dass eine Pressemitteilung vom 18. Juni 2025 als Exhibit 99.1 beigefügt ist.
  • erklärt, dass die Informationen im Bericht—mit Ausnahme spezifischer Arztzitate im Anhang—durch Verweis in mehreren noch gültigen Form S-8-Registrierungserklärungen aufgenommen sind.
  • enthält keine Finanzberichte, Gewinnkennzahlen oder Details zu wesentlichen Transaktionen.
  • wird von der Unternehmenssekretärin Annelies Denecker unterzeichnet.
Die Einreichung dient somit dazu, die Pressemitteilung vom 18. Juni 2025 in den SEC-Akten zu erfassen, liefert jedoch keine neuen operativen oder finanziellen Informationen, die die aktuelle Investmentthese beeinflussen würden.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine 6-K; no new financial data or guidance disclosed.

The filing simply furnishes a press release as Exhibit 99.1 and links its contents to several equity compensation Form S-8 registrations. Because the 6-K lacks revenue, earnings, pipeline updates, or transactional details, it should be viewed as a procedural submission with neutral investor impact. Any substantive assessment would depend on the underlying press release, which is not included in the text provided.

TL;DR: Administrative compliance step; governance posture unchanged.

Management fulfills disclosure obligations by integrating the June 18 press release into the U.S. securities record and maintaining consistency across existing S-8 registrations. The signature by the Company Secretary and the clear indication of Form 20-F reporting status align with standard best practices. There are no signals of governance risk or strategic shifts in this document.

Galapagos NV (simbolo: GLPG) ha presentato un modulo 6-K il 20 giugno 2025. La comunicazione ha principalmente carattere amministrativo. Essa:

  • Annuncia che un comunicato stampa datato 18 giugno 2025 è allegato come Exhibit 99.1.
  • Dichiara che le informazioni contenute nel rapporto—ad eccezione delle citazioni specifiche di medici presenti nell'allegato—sono incorporate per riferimento in diversi moduli di registrazione Form S-8 ancora validi.
  • Non include bilanci, indicatori di redditività o dettagli su operazioni rilevanti.
  • È firmata dalla Segretaria Aziendale Annelies Denecker.
La presentazione ha quindi lo scopo di inserire il comunicato stampa del 18 giugno 2025 nel registro della SEC, ma non fornisce nuove informazioni operative o finanziarie che possano influenzare l'attuale tesi di investimento.

Galapagos NV (símbolo: GLPG) presentó un Formulario 6-K el 20 de junio de 2025. La presentación es principalmente de carácter administrativo. Este:

  • Anuncia que un comunicado de prensa fechado el 18 de junio de 2025 se adjunta como Exhibit 99.1.
  • Indica que la información en el informe—excepto las citas específicas de médicos en el anexo—se incorpora por referencia en varios formularios de registro Form S-8 vigentes.
  • No contiene estados financieros, métricas de ganancias ni detalles sobre transacciones materiales.
  • Está firmado por la Secretaria de la Compañía, Annelies Denecker.
Por lo tanto, la presentación sirve para incluir el comunicado de prensa del 18 de junio de 2025 en el registro de la SEC, pero no aporta nueva información operativa o financiera que pueda afectar la tesis de inversión actual.

Galapagos NV(티커: GLPG)는 2025년 6월 20일에 Form 6-K를 제출했습니다. 이 제출은 주로 행정적인 성격을 띠고 있습니다. 내용은 다음과 같습니다:

  • 2025년 6월 18일자 보도자료가 Exhibit 99.1로 제공되었음을 알립니다.
  • 보고서 내 정보는—첨부된 특정 의사 인용문을 제외하고—여러 유효한 Form S-8 등록 서류에 참조로 포함되어 있음을 명시합니다.
  • 재무제표, 수익 지표 또는 주요 거래 내역은 포함되어 있지 않습니다.
  • 회사 비서인 Annelies Denecker가 서명하였습니다.
따라서 이 제출은 2025년 6월 18일 보도자료를 SEC 기록에 포함시키기 위한 것이며, 현재 투자 논리에 영향을 줄 새로운 운영 또는 재무 정보를 제공하지 않습니다.

Galapagos NV (symbole : GLPG) a déposé un formulaire 6-K le 20 juin 2025. Cette soumission est principalement de nature administrative. Elle :

  • Annonce qu’un communiqué de presse daté du 18 juin 2025 est fourni en tant qu’Exhibit 99.1.
  • Indique que les informations contenues dans le rapport—à l’exception des citations spécifiques de médecins dans l’exhibit—sont incorporées par référence dans plusieurs déclarations d’enregistrement Form S-8 en cours.
  • Ne contient pas d’états financiers, de mesures de résultats ou de détails sur des transactions importantes.
  • Est signée par la secrétaire de la société, Annelies Denecker.
Le dépôt sert donc à inclure le communiqué de presse du 18 juin 2025 dans le dossier de la SEC, mais ne fournit pas de nouvelles informations opérationnelles ou financières susceptibles d’affecter la thèse d’investissement actuelle.

Galapagos NV (Ticker: GLPG) reichte am 20. Juni 2025 ein Formular 6-K ein. Die Einreichung ist hauptsächlich administrativer Natur. Sie:

  • kündigt an, dass eine Pressemitteilung vom 18. Juni 2025 als Exhibit 99.1 beigefügt ist.
  • erklärt, dass die Informationen im Bericht—mit Ausnahme spezifischer Arztzitate im Anhang—durch Verweis in mehreren noch gültigen Form S-8-Registrierungserklärungen aufgenommen sind.
  • enthält keine Finanzberichte, Gewinnkennzahlen oder Details zu wesentlichen Transaktionen.
  • wird von der Unternehmenssekretärin Annelies Denecker unterzeichnet.
Die Einreichung dient somit dazu, die Pressemitteilung vom 18. Juni 2025 in den SEC-Akten zu erfassen, liefert jedoch keine neuen operativen oder finanziellen Informationen, die die aktuelle Investmentthese beeinflussen würden.

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-37384

GALAPAGOS NV
(Translation of registrant's name into English)

Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, except for the quotes of Omotayo Fasan, M.D., and Maria Kuipers, M.D., included in Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, and 333-283361).

On June 18, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated June 18, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

        GALAPAGOS NV    
    (Registrant)
     
   
Date: June 20, 2025       /s/ Annelies Denecker    
    Annelies Denecker
    Company Secretary
   

Source: View Original Filing on SEC EDGAR

FAQ

Why did Galapagos NV (GLPG) file a Form 6-K on 20 June 2025?

To furnish a press release dated 18 June 2025 and incorporate its contents (minus two physician quotes) into existing Form S-8 registration statements.

Does the 6-K include any new financial results for GLPG?

No. The filing contains no earnings figures, balance-sheet data, or guidance.

Which registration statements are affected by this incorporation by reference?

Thirteen Form S-8 files, including 333-204567 through 333-283361, now incorporate the furnished information.

Who signed the 6-K for Galapagos NV?

Company Secretary Annelies Denecker signed the report.

Is there any material transaction disclosed in this 6-K?

No. The document is purely procedural and does not announce mergers, financings, or other transactions.
Stock GLPG logo
Galapagos Nv

NASDAQ:GLPG

GLPG Rankings

#2034 Ranked by Market Cap
N/A Ranked by Dividends

GLPG Latest News

Oct 1, 2024
Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos’ CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area
Aug 1, 2024
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology
May 30, 2024
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Jan 3, 2024
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
Nov 6, 2023
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care

GLPG Latest SEC Filings

Jun 25, 2025
[6-K] Galapagos NV Current Report (Foreign Issuer)

GLPG Stock Data

1.78B
65.90M
48.23%
3.29%
Biotechnology
Healthcare
Link
Belgium
Mechelen